Quality of Radiotherapy Reporting in Randomized Controlled Trials of Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma: A Systematic Review

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 2, 2009, Pages 492-498

  Bekelman, Justin E ^a   Yahalom, Joachim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hodgkin's lymphoma; Non Hodgkin's lymphoma; Quality of radiotherapy reporting; Randomized controlled trials; Systematic review

Indexed keywords

DOSIMETRY; QUALITY ASSURANCE; TARGETS; TOTAL QUALITY MANAGEMENT;

HODGKIN'S LYMPHOMA; NON-HODGKIN'S LYMPHOMA; QUALITY OF RADIOTHERAPY REPORTING; RANDOMIZED CONTROLLED TRIALS; SYSTEMATIC REVIEW;

RADIOTHERAPY;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; HEALTH CARE QUALITY; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SYSTEMATIC REVIEW;

CLINICAL TRIALS, PHASE III AS TOPIC; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; PRESCRIPTIONS; PUBLISHING; QUALITY ASSURANCE, HEALTH CARE; RADIATION ONCOLOGY; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR BURDEN;

EID: 58149350284     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.04.058     Document Type: Article

References (33)

1. Chalmers T.C., Smith Jr. H., Blackburn B., et al. A method for assessing the quality of a randomized control trial. Control Clin Trials 2 (1981) 31-49
2. Begg C., Cho M., Eastwood S., et al. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 276 (1996) 637-639
3. Moher D., Schulz K.F., and Altman D.G. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357 (2001) 1191-1194
4. Altman D.G., Schulz K.F., Moher D., et al. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134 (2001) 663-694
5. Ottevanger P.B., Therasse P., van de Velde C., et al. Quality assurance in clinical trials. Crit Rev Oncol Hematol 47 (2003) 213-235
6. Bentzen S.M. Towards evidence based radiation oncology: Improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother Oncol 46 (1998) 5-18
7. The NCCN Non-Hodgkin's Lymphoma Clinical Practice Guidelines in Oncology, version 1.2007. ©2007 National Comprehensive Cancer Network, Inc. Available from: http://www.nccn.org. Accessed October 10, 2007.
8. Laskar S., Gupta T., Vimal S., et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need?. J Clin Oncol 22 (2004) 62-68
9. Nachman J.B., Sposto R., Herzog P., et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 (2002) 3765-3771
10. Carde P. The chemotherapy/radiation balance in advanced Hodgkin's lymphoma: Overweight which side?. J Clin Oncol 23 (2005) 9058-9062
11. Radiation Therapy Oncology Group. RTOG procedure manual (2005), RTOG, Philadelphia. http://www.rtog.org/pdf_document/manual.pdf Available from: http://www.rtog.org/pdf_document/manual.pdf. Accessed October 20, 2007
12. Kober T., Trelle S., and Engert A. Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. J Natl Cancer Inst 98 (2006) 620-625
13. Landis J., and Koch G. The measurement of observer agreement for categorical data. Biometrics 33 (1977) 159-174
14. Yahalom J. Principles, indications, and techniques of radiation therapy of lymphomas. In: Canellos G., Lister T.A., and Young B. (Eds). The Lymphomas. 2nd edition (2006), WB Saunders, Philadelphia
15. Yahalom J., and Mauch P. The involved field is back: Issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 13 Suppl. 1 (2002) 79-83
16. Muller R.P., and Eich H.T. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG): Introduction, continuing work, and results of the radiotherapy reference panel. Strahlenther Onkol 181 (2005) 557-566
17. Girinsky T., van der Maazen R., Specht L., et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol 79 (2006) 270-277
18. Fabian C.J., Mansfield C.M., Dahlberg S., et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease: A Southwest Oncology Group randomized study. Ann Intern Med 120 (1994) 903-912
19. Duhmke E., Diehl V., Loeffler M., et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 36 (1996) 305-310
20. Pajak T.F., Laramore G.E., Marcial V.A., et al. Elapsed treatment days-A critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 20 (1991) 13-20
21. Fietkau R., Rodel C., Hohenberger W., et al. Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: Results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys 67 (2007) 1008-1019
22. Gebski V., Lagleva M., Keech A., et al. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: A clinical perspective. J Natl Cancer Inst 98 (2006) 26-38
23. Atagi S., Kawahara M., Tamura T., et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: A phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol 35 (2005) 195-201
24. Bosch W., Matthews J., Straube W., et al. QuASAR: Quality assurance submission, analysis, and review system for advanced technology clinical trials in radiation therapy. In: Bissonnette J.-P. (Ed). Proceedings of the XVth International Conference on the Use of Computers in Radiation Therapy, June 4-7, 2007 (2007), Novel Digital Publishing, Toronto, Canada. Oakville, ON, Canada 98-102
25. Eich H.T., and Muller R.P. The radiotherapy reference panel experiences and results of the German Hodgkin Study Group (GHSG). Eur J Haematol 75 Suppl. (2005) 98-105
26. Ikeda H. Quality assurance activities in radiotherapy. Jpn J Clin Oncol 32 (2002) 493-496
27. Poortmans P.M., Davis J.B., Ataman F., et al. The quality assurance programme of the Radiotherapy Group of the European Organisation for Research and Treatment of Cancer: Past, present and future. Eur J Surg Oncol 31 (2005) 667-674
28. Ferreira I.H., Dutreix A., Bridier A., et al. The ESTRO-QUALity assurance network (EQUAL). Radiother Oncol 55 (2000) 273-284
29. Ibbott G. The Radiological Physics Center's QA Activities. 2007. Available from: http://rpc.mdanderson.org/RPC/Publications/RPC_Presentations/RPC%20Refresher%20Course%202007.pdf. Accessed October 20, 2007.
30. Eich H.T., Gossmann A., Engert A., et al. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma-Analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 69 (2007) 1187-1192
31. Diez P., Hoskin P.J., and Aird E.G. Treatment planning and delivery of involved field radiotherapy in advanced Hodgkin's disease: Results from a questionnaire-based audit for the UK Stanford V regimen vs ABVD clinical trial quality assurance programme (ISRCTN 64141244). Br J Radiol 80 (2007) 816-821
32. Hill C.L., LaValley M.P., and Felson D.T. Discrepancy between published report and actual conduct of randomized clinical trials. J Clin Epidemiol 55 (2002) 783-786
33. Soares H.P., Daniels S., Kumar A., et al. Bad reporting does not mean bad methods for randomised trials: Observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ 328 (2004) 22-24